 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...6970717273747576777879...100101» |
- Herceptin (trastuzumab) / Roche
Can some ER+/HER2+ patients be safely spared from treatment with chemotherapy plus herceptin? (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1174;
The aim is to show that ER+/HER2+ patients predicted to respond less well to ET alone using IL6ST levels, gain additional benefit from chemotherapy plus Herceptin.Patients: • Cohort A - 32 post-menopausal women (PMW) with large ER+/HER2+ BC treated with neoadjuvant (3-6 months) then adjuvant letrozole. • IL6ST levels can differentiate ER+/HER2+ BCs who respond well to ET alone and those with a poor clinical response who have a higher risk of recurrence.• NR to ET have increased expression of PI3K and MAPK pathways, consistent with active HER2 signalling.• Analysis of cohort B is underway and will elucidate the benefit in terms of recurrence-free and overall breast cancer specific survival from the addition of chemotherapy plus Herceptin to the group predicted to respond less well to ET using IL6ST.• There is potential role for IL6ST in selecting ER+/HER2+ patients that require and benefit from HER2-targeted therapies.
- letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
In-depth genomic analysis of acquired resistance to multiple sequential lines of endocrine therapy in breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1148;
Only KMT2C was identified as enriched in resistant tumours when comparing sensitive to only those that acquired resistance to 1st line LET. When comparing sensitive tumours to only those that had acquired resistance to multiple lines of ET (LET and TAM +/- AN and EX), sensitives were significantly enriched for mutations in CCDC141 and SLC9A9 and multi-drug resistant (MDR) tumours were significantly enriched for mutations in 11 genes including ESR1 and GATA3, and genes involved in cell adhesion (CDH1, FLG, FLG2 and FREM2).
- Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
Real-world treatment patterns and clinical outcomes among women with HR+/HER2- advanced or metastatic breast cancer treated in real-world settings in Italy and Germany (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1113;
Further follow-up is required for longitudinal analysis and to estimate overall survival. Funding: Pfizer
- Adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen for hormone receptor-positive breast cancer in women younger than 35 (ASPAIT): A multicenter randomized clinical trial (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1030;
P3
Patients who allergy to goserelin, leuprorelin, tamoxifen or AIs...Arm B: Exemestane 25mg, letrozole 2.5mg or anastrozole 1mg orally daily...Invasive Breast Cancer Recurrence-Free Interval. Adverse Effects Rate.
- Ibrance (palbociclib) / Pfizer
A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose Palbo (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_996;
P2
Survival data is not yet mature and will be updated at the presentation. However, preliminary efficacy data appears comparable to prior report.
- letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Ribecca - a phase IIIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole: results of the third interim analysis (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_967;
No new safety signals were detected. This is in line with data published from the pivotal phase III studies MONALEESA-2, MONALEESA-3 and MONALEESA-7.
- letrozole / Generic mfg.
Estrogen receptor β agonist S-Equol promotes letrozole sensitivity of endocrine therapy resistant breast cancer cells by upregulating FOXO3 expression (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_956;
Collectively, our results suggest that S-equol exhibits its antitumor activity by targeting forkhead box transcription factors and that S-equol might be an effective treatment strategy in treating / preventing breast cancer recurrence. (Supported by BCRP 151884/DOD grant W81XWH-16-1-0294).
- Ibrance (palbociclib) / Pfizer
Palbociclib in advanced male hormone positive breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_938;
Palbociclib was combined with AI+GNRH in 13 pts (50%), fulvestrant+GNRH in 4 pts (15%), letrozole alone in 3 pts (13%), and fulvestrant alone in 6 pts (23%). Palbociclib provides benefit for MBC patients with the majority of men in this study achieving clinical response to treatment.
- Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_920;
Acknowledging the limitations of this non-randomized EHR database analysis, these data support the value of palbociclib when added to letrozole in improving long-term outcomes in the real-world setting. Funding: Pfizer Inc.
- Afinitor (everolimus) / Novartis
Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_918;
Of these, 726 patients received EE in 1L (N=127), 2L (N=326), or 3L (N=273). In this cohort, 72.3% of patients were diagnosed between 2011-2014, and 27.7% were diagnosed after 1/2015, and most (94.6%) were treated in the community setting.
- Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
A Phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_875;
P1
In this cohort, 72.3% of patients were diagnosed between 2011-2014, and 27.7% were diagnosed after 1/2015, and most (94.6%) were treated in the community setting. This Phase Ib study of GDC-0077 in combination with letrozole with and without pabocicilb demonstrated a manageable safety profile combining GDC-0077 at its single agent recommended Phase II dose of 9 mg with letrozole with and without palbociclib at standard doses, with no evidence for DDI, high GDC-0077 dose intensity, and promising preliminary anti-tumor activity.
- Kisqali (ribociclib) / Novartis
Real-world efficacy of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: second interim analysis from the RIBANNA study (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_861;
Based on the baseline demographics data, RIB (CDK4/6 inhibitor) treatment was found to be very well adopted among premenopausal and postmenopausal patients with HR+/HER2- aBC. The second interim analysis is planned for October 2019.
- Ibrance (palbociclib) / Pfizer
Genomic aberrations in circulating tumor DNAs associated with progression in palbociclib-treated metastatic breast cancer patients (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_713;
Results of this study show that genomic aberrations in ctDNA were associated with progression in MBC pts receiving palbociclib-containing regimens. Further research is needed to validate these findings in larger independent studies.
- letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Bioitalee - biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (abc) (nct03439046) (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_700;
Interestingly, MYC gain, TP53 mutations, alterations in genes of the HER family and CDK4/6 pathway were more likely detected in patients with early PD suggesting these as potential markers of intrinsic resistance to first-line treatment with ribociclib and letrozole. Further analyses for biomarker dynamics and pharmacogenomics are ongoing.
- letrozole / Generic mfg.
Racial/ethnic differences in tumor infiltrating lymphocytes (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_673;
We found significant % sTILs differences in ethnicity, specifically Asian (35%), Pacific Islander (38.5%) and Other (46%) category compared to White (19%) Table 1. There were no differences found in sTILs according to age, BMI or stage.
- Ibrance (palbociclib) / Pfizer
A retrospective study of 27 patients with ER-positive, HER2 negative metastatic breast cancer treated with concomitant palbociclib and radiation therapy (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_662;
Caution should be exercised when a large volume is irradiated, and when the dose per fraction is high. It remains unsure whether the interruption-causing side effects of Palbociclib was based on synergistic toxicity with radiation therapy.
- Tykerb (lapatinib) / Novartis, letrozole / Generic mfg.
A novel phytoalexin, glyceollins, trigger anti-proliferative effects in aromatase inhibitor resistant breast cancer cells (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_633;
Taken together, these results suggest that dual inhibition using glyceollins and lapatinib may have potential as a novel combination therapy approach for postmenopausal patients with hormone-dependent, letrozole-resistant breast tumors. This work was also supported by NIH grant 1SC1GM126617 awarded to SL Tilghman.
- Kisqali (ribociclib) / Novartis
The cardo-oncology concerns of combining tamoxifen and ribociclib based on the TEEL trial (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_630;
The phase I expansion was not completed. There were 5 events of prolonged QTC, one event was determined to be a DLT.
- Kisqali (ribociclib) / Novartis
Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2- advanced breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_623;
P3
Analysis of PROs demonstrated that TTD ? 10% in global health status and emotional functioning were prolonged with RIB vs PBO.
- Verzenio (abemaciclib) / Eli Lilly
Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3) (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_620;
P3
NPJ Breast Cancer . 2018;4:41.Clinical trial information : NCT02246621This study was funded by Eli Lilly and CompanyTable: Objective Response Rate N= total number of patients in each subgroup; n= number of responder patients; NA=not applicable*Response rate not reported for bone-only disease because majority of lesions were not measurable
- letrozole / Generic mfg.
Time-course DNA and RNA profiling reveals down regulation of all members of the sulfotransferase A1 subfamily during neoadjuvant therapy with aromatase inhibitors (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_595;
Background: The NEO-LET-EXE trial examines the neoadjuvant and sequential administration of the aromatase inhibitor (AI) letrozole (Femar/Femara) and the aromatase inactivator exemestane (Aromasin)...These findings may reflect an early adaptation process caused by the AI-induced estrogen depression. A low rate of CYP19A1 copy number changes could be revealed during the first 4 months of neoadjuvant AI therapy in vivo .
- Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
Real-world benefit of CDK4/6 inhibitor and endocrine therapy combination in metastatic breast cancer and correlation with neutropenia (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_582;
In addition, patients with a higher ANC were found to have a higher risk for early disease progression. This has implication for clinical practice [i.e., frequent dose delay and/or dose reduction based on ANC threshold of 1000/uL may not be an optimal approach.
- Afinitor (everolimus) / Novartis
Everolimus in first-line treatment of advanced premenopausal breast cancer: Results from MIRACLE (everoliMus trIal foR AdvanCed premenopausaL brEast cancer) study (Stars at Night Ballroom 1&2 - 3rd Level) - Sep 25, 2019 - Abstract #SABCS2019SABCS_532;
The results support the use of everolimus plus letrozole in this population. Furthermore, everolimus can indeed overcome endocrine resistance, addition of everolimus to the same endocrine agent can still be effective even after previous progression.
- Kisqali (ribociclib) / Novartis
A phase 2 randomized, double-blind, placebo-controlled study of ribociclib or placebo in combination with endocrine therapy for the treatment of premenopausal and postmenopausal Chinese women with HR+, HER2-, advanced breast cancer (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_510;
Secondary endpoints are overall survival, overall response rate, clinical benefit rate, time to response, duration of response, and time to deterioration in ECOG PS. The objectives for the PK cohort are to characterize PK parameters of the RIB + LET combination, and of the RIB metabolites.
- letrozole / Generic mfg., Kisqali (ribociclib) / Novartis, paclitaxel / Generic mfg.
Immune response following neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: A correlative analysis of the SOLTI-1402 CORALLEEN phase 2 randomized trial (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_499;
An increase in TILs following 24-weeks of R+L occurs in ~30% of pts with high-risk Luminal B tumors, regardless of tumor ROR response. These findings suggest that immune checkpoint blockade might be an interesting strategy to explore in patients with a low ROR response after R+L.
- Afinitor (everolimus) / Novartis
AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_478;
Heterogeneity in response to endocrine-based therapy following the identification of an AKT1 alteration may be related to tumor-extrinsic factors, the AKT1 allelic fraction, or cooperativity between multiple resistance drivers. Further research is needed to confirm these findings and guide optimal therapeutic sequencing strategies for patients with HR+/HER2- AKT1 mutant MBC.
- Afinitor (everolimus) / Novartis
Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (?25) (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_474;
The combination of an AI and everolimus was overall well tolerated. Our study suggested that baseline expression levels of key pathways were associated with response to neoadjuvant AI plus everolimus.
- Verzenio (abemaciclib) / Eli Lilly
Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_466;
P3
Abemaciclib in combination with ET demonstrates a tolerable safety profile and consistent efficacy benefit across all age subgroups examined, supporting the use of this combination in elderly patient populations. Despite the limited number of patients in the ?75 group with potentially confounding comorbidities, the safety data suggest that patient education and appropriate management of toxicities, including dose adjustments and use of supportive medication for gastrointestinal toxicities, could maximize the benefit of abemaciclib.
- Kisqali (ribociclib) / Novartis
A 'real world' experience of CDK4/6 inhibition with ribociclib and endocrine therapy in hormone receptor positive metastatic breast cancer in Australia (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_454;
Details of adjuvant therapy received and the tolerability of the treatment combination including dose interruptions, dose reductions and significant adverse events of interest related to ribociclib will be assessed. Secondary aims include time to treatment progression and progression free survival for the ribociclib and AI combination, and to explore the disease course post progression, including clinician choice of subsequent lines of therapy in routine clinical practice.
- Ibrance (palbociclib) / Pfizer
Comprehensive tumor sequencing to identify biomarkers of palbociclib response: first report of the PROMISE study (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_452;
We observed high frequencies of known targetable alterations in PIK3CA and ESR1 , including in patients that progress, which is consistent with previous reports. RNA sequencing data will be presented at the meeting.
- Z-endoxifen hydrochloride / National Cancer Institute
Protein Kinase C Beta 1 (PKCβ1), a novel drug target of Z-endoxifen, inhibits growth of estrogen receptor positive (ER+) breast cancer via activation of the NF-kB transcription factor RelA (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_437;
Notably, PKC?1-silencing induces the protein expression of the NF-?B transcription factor RelA in an ER?-independent manner, which appears to contribute to PKC?1-mediated growth inhibition. Current studies are ongoing to evaluate the impact of RelA silencing on Z-endoxifen mediated growth inhibition.
- letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica
Vaginal and sexual health of hormone-receptor positive breast cancer survivors on oral endocrine therapy: A cross-sectional study (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_427;
English-speaking women with HR+ breast cancer who had a treatment history with Tamoxifen or an AI (Anastrozole, Letrozole or Exemestane) for ? Our results support the notion that side effect management and patient-provider communication should be prioritized to optimize the vaginal and sexual health of women with HR+ breast cancer receiving oral ET.Women may be unaware of potential treatment options that can help manage side effects accompanying this therapy, and possibly accept these as a new standard of life.
- letrozole / Generic mfg.
Characteristics and risk factors of nonalcoholic fatty liver disease and liver fibrosis in breast cancer survivors (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_421;
Breast cancer survivors with baseline or incident NAFLD had distinct characteristics in terms of body composition and metabolic profiles. Lifestyle intervention to ameliorate insulin resistance needs to be underlined to prevent development of NAFLD and/or progression of liver fibrosis in breast cancer survivors.
- letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Ribociclib + letrozole in patients with HR+, HER2- advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_415;
P3
AEs associated with RIB + LET combination therapy were manageable and often reversible. This interim safety analysis is consistent with previous phase 3 trials of RIB + LET and further supports its use for first-line treatment of HR+, HER2- ABC in both men and women of any menopausal status in real-world settings.
- Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Abemaciclib following Palbociclib in metastatic breast cancer (MBC): characteristics of patients (pts) with durable response (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_398;
Conclusions ABT can result in durable response in selected pts who progressed on prior Palbociclib. Prospective studies are warranted to establish which factors might contribute to the success of a specific sequence of therapies with CDK4/6is.
- Halaven (eribulin mesylate) / Eisai
A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study) (Hall 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_394;
P2
ClinicalTrials.gov identifier: NCT03795012. First patient enrolled on June 24th , 2019.
- | Reolysin (pelareorep) / Oncolytics, Andrus Reo
New P1 trial, PD(L)-1 Biomarker: AWARE-1: A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (clinicaltrials.gov) - Sep 24, 2019
P1, N=38, Recruiting, Sponsor: Oncolytics Biotech
- letrozole / Generic mfg.
A neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer (Hall 3) - Sep 23, 2019 - Abstract #SABCS2019SABCS_320;
P1
is required for the growth promoting effects of PRR11.These data suggest that 1) PRR11 is a mediator of resistance to antiestrogens via amplification of PI3K/AKT signaling, and 2) PI3K? is a potential therapeutic target in ER+ BCs harboring PRR11 amplification.
- letrozole / Generic mfg.
Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI) (Hall 3) - Sep 23, 2019 - Abstract #SABCS2019SABCS_228;
There was no significant improvement in OS with L, but L continued to provide a significant improvement in BCFI and DR. Support: U10CA180868, -180822; UG1CA189867; Korea Health Technology R&D Project; Novartis.
- Primary results of SOLTI-1402/CORALLEEN phase 2 trial of neoadjuvant ribociclib plus letrozole versus chemotherapy in PAM50 Luminal B early breast cancer: An open-label, multicenter, two-arm, randomized study (Hall 3) - Sep 23, 2019 - Abstract #SABCS2019SABCS_137;
Neoadjuvant ribociclib and letrozole in high-risk Luminal B breast cancer achieves similar rates of ROR-low disease at surgery as multi-agent chemotherapy. Future studies in high-risk early breast cancer evaluating the survival outcomes and quality of life of this combination in the absence of cytotoxic therapy are justified.
- | amcenestrant (SAR439859) / Sanofi
Enrollment open, Monotherapy, Metastases: AMEERA-3: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (clinicaltrials.gov) - Sep 23, 2019
P2, N=282, Recruiting, Sponsor: Sanofi
Future studies in high-risk early breast cancer evaluating the survival outcomes and quality of life of this combination in the absence of cytotoxic therapy are justified. Not yet recruiting --> Recruiting
- | Afinitor (everolimus) / Novartis
Journal: Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. (Pubmed Central) - Sep 22, 2019
This review provides clinicians with an overview on the available data regarding endocrine treatment of hormone receptor positive (HR+) metastatic breast cancer (MBC) in premenopausal women and summarizes the treatment options available in routine clinical practice. Knowledge of an up-to-date therapeutic approach in women with premenopausal HR+ MBC will lead to better disease management, thereby improving disease control and quality of life while minimizing side effects.
- | letrozole / generics, docetaxel / generics
Clinical, Journal: Acute Generalized Exanthematous Pustulosis Induced by Docetaxel and Recurrent With Letrozole: A Case Report. (Pubmed Central) - Sep 22, 2019
Knowledge of an up-to-date therapeutic approach in women with premenopausal HR+ MBC will lead to better disease management, thereby improving disease control and quality of life while minimizing side effects. No abstract available
- | letrozole / generics
Journal: Cloning and Characterization of wnt4a gene in a natural triploid teleost, Qi river crucian carp (Carassius auratus). (Pubmed Central) - Sep 22, 2019
In the sex-reversed testis induced by letrozole treatment, the expression level of CA-wnt4a was significantly downregulated. When CA-wnt4a expression was inhibited by injection of FH535 (an inhibitor of canonical Wnt/β-catenin signal pathway) in the ovaries, levels of cyp19a1a, foxl2 mRNA were significantly downregulated, while sox9b and cyp11c1 were upregulated, which suggested that together with Foxl2-leading estrogen pathway, CA-wnt4a signaling pathway might be involved in ovarian differentiation and repression of the male pathway gene expression in Qi river crucian carp.
- | letrozole / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
New P3 trial, Monotherapy: NRG-GY019: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Sep 18, 2019
P3, N=450, Recruiting, Sponsor: NRG Oncology
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: INPHASE: A Phase ? Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer (clinicaltrials.gov) - Sep 18, 2019
P2, N=60, Recruiting, Sponsor: Jinming Yu
- Ibrance (palbociclib) / Pfizer, Avastin (bevacizumab) / Roche, paclitaxel / Generic Mfg.
Serous ovarian cancer treated with palbociclib and letrozole (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_872;
She received carboplatin/paclitaxel/bevacizumab combination for 8 months and stopped in view that the patient opted for a drug holiday...She was then treated with carboplatin & pegylated liposomal doxorubicin for 6 cycles...In May 2017, her CA15-3 was increasing from 55U/mL to 77U/mL, and letrozole was changed to tamoxifen...In this case, palbociclib and letrozole have shown a prolonged PFS of more than 14 months and an excellent toxicity profile. This could present a potential therapeutic role of CDK4/6 inhibition in recurrent ovarian cancers.
- Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap, Kisqali (ribociclib) / Novartis, paclitaxel / Generic Mfg.
Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_409;
P2
Funding: Novartis Pharmaceuticals Corporation. Clinical trial identification: NCT03839823.
- | Ibrance (palbociclib) / Pfizer
Trial primary completion date, Combination therapy, Metastases: Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) - Sep 16, 2019
P2, N=88, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Clinical trial identification: NCT03839823. Trial primary completion date: Sep 2019 --> Sep 2020
- | Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg., Perjeta (pertuzumab) / Roche
Clinical, P2 data, Journal: First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. (Pubmed Central) - Sep 16, 2019
P2
Induction intravenous docetaxel every 3 weeks or paclitaxel every week could be administered for 18 to 24 weeks at the investigator's discretion (decided before but given after random assignment)...Pertuzumab plus trastuzumab and an AI is effective for the treatment of HER2-positive MBC/LABC. The safety profile was consistent with previous trials of pertuzumab plus trastuzumab.